D1400147 + D14000136 + D14000137 + Epanova®
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioavailability
Conditions
Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Trial Timeline
Feb 12, 2015 → Jul 27, 2015
NCT ID
NCT02359045About D1400147 + D14000136 + D14000137 + Epanova®
D1400147 + D14000136 + D14000137 + Epanova® is a phase 1 stage product being developed by AstraZeneca for Relative Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT02359045. Target conditions include Relative Bioavailability, AUC, Cmax.
What happened to similar drugs?
1 of 1 similar drugs in Relative Bioavailability were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02359045 | Phase 1 | Completed |
Competing Products
6 competing products in Relative Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab + Sonelokimab | MoonLake Immunotherapeutics | Phase 1 | 23 |
| ABT-333 | AbbVie | Phase 1 | 29 |
| BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg | AstraZeneca | Phase 1 | 29 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 40 |
| Sulfatinib T capsule + Sulfatinib R capsule | HUTCHMED | Phase 1 | 23 |
| Tebipenem tablet form | Spero Therapeutics | Phase 1 | 19 |